Evidence map›Paper›PMID 25730467›Full record

Trial reportAmerican journal of respiratory and critical care medicine2015

Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus.

Maximillian S Habibi, Agnieszka Jozwik, Spyridon Makris, Jake Dunning, Allan Paras, John P DeVincenzo, Cornelis A M de Haan, Jens Wrammert, Peter J M Openshaw, Christopher Chiu and 1 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 187 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
187citing papers in PubMed, 1 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

187 citing papers in PubMed, 1 synthesis or guideline pooled it, 284 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

127 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Maximillian S Habibi1 National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Agnieszka Jozwik
Spyridon Makris
Jake Dunning
Allan Paras
John P DeVincenzo
Cornelis A M de Haan
Jens Wrammert
Peter J M Openshaw
Christopher Chiu
Mechanisms of Severe Acute Influenza Consortium Investigators
Imperial College London · GBEmory University · USUniversity of Tennessee Health Science Center · USUtrecht University · NL

Funding

Medical Research Council G0902266Medical Research Council G1000758Medical Research Council MC_G1001212Wellcome TrustWellcome Trust 087805/Z/08/ZWellcome Trust 090382/Z/09/Z
6 · The paper itself

Abstract

rationaleDespite relative antigenic stability, respiratory syncytial virus (RSV) reinfects throughout life. After more than 40 years of research, no effective human vaccine exists and correlates of protection remain poorly defined. Most current vaccine candidates seek to induce high levels of RSV-specific serum neutralizing antibodies, which are associated with reduced RSV-related hospitalization rates in observational studies but may not actually prevent infection.

objectivesTo characterize correlates of protection from infection and the generation of RSV-specific humoral memory to promote effective vaccine development.

methodsWe inoculated 61 healthy adults with live RSV and studied protection from infection by serum and mucosal antibody. We analyzed RSV-specific peripheral blood plasmablast and memory B-cell frequencies and antibody longevity. MEASUREMENTS AND MAIN

resultsDespite moderately high levels of preexisting serum antibody, 34 (56%) became infected, of whom 23 (68%) developed symptomatic colds. Prior RSV-specific nasal IgA correlated significantly more strongly with protection from polymerase chain reaction-confirmed infection than serum neutralizing antibody. Increases in virus-specific antibody titers were variable and transient in infected subjects but correlated with plasmablasts that peaked around Day 10. During convalescence, only IgG (and no IgA) RSV-specific memory B cells were detectable in peripheral blood. This contrasted with natural influenza infection, in which virus-specific IgA memory B cells were readily recovered.

conclusionsThis observed specific defect in IgA memory may partly explain the ability of RSV to cause recurrent symptomatic infections. If so, vaccines able to induce durable RSV-specific IgA responses may be more protective than those generating systemic antibody alone.

Indexed as

Immunologic MemoryAdolescentAdultAntibodies, ViralB-LymphocytesFemaleHumansImmunoglobulin AMaleMiddle AgedRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsYoung AdultAntibodies, ViralImmunoglobulin Aantibody-secreting cellsimmunologic memorymucosal immunitynontherapeutic human experimentationrespiratory syncytial virus vaccines

Identifiers

PMID25730467
PMCPMC4435460
OpenAlexW2130386320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.